ArticleMolecular cancer therapeutics2007
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity.
Article in Molecular cancer therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.The pharmacogenomics journal · 2013Pooled it
- A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide.Cancer research and treatment · 2019Trial
- Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.Pediatric blood & cancer · 2012Trial
- KDM5D expression is lost in cisplatin‑resistant neuroblastoma cells.Oncology reports · 2026Article
- Clinical outcomes of chemotherapy in cancer patients with different ethnicities.Cancer reports (Hoboken, N.J.) · 2023Review
- PotentFrontiers in oncology · 2023Article
- Sex differences in drug effects and/or toxicity in oncology.Current research in pharmacology and drug discovery · 2023Article
- Confounding factors in the assessment of oral mucositis in head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Possible Mechanisms of Subsequent Neoplasia Development in Childhood Cancer Survivors: A Review.Cancers · 2021Review
- Sex Differences in the Triad of Acquired Sensorineural Hearing Loss.International journal of molecular sciences · 2021Review
- Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation.Scientific reports · 2020Article
- Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer.Cancers · 2020Review
- Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.The pharmacogenomics journal · 2019Article
- Specification of Subject Sex in Oncology-Related Animal Studies.Acute and critical care · 2018Article
- Sex Differences in Cancer: Epidemiology, Genetics and Therapy.Biomolecules & therapeutics · 2018Review
- ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.Scientific reports · 2017Article
- Downregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.Cellular signalling · 2017Article
- Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender DifferencesAsian Pacific journal of cancer prevention : APJCP · 2017Review
- Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.Journal of breast cancer · 2016Article
- Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Large interindividual variance is observed in both response and toxicity associated with chemotherapy. Our goal is to identify factors that contribute to chemotherapy-induced toxicity. To this end, we used EBV-transformed B-lymphoblastoid HapMap cell lines derived from 30 Yoruban trios (African descent) and 30 Centre d' Etude du Polymorphisme Humain (CEPH) trios (European descent) to evaluate population- and gender-specific differences in cytotoxicity of carboplatin, cisplatin, daunorubicin, and etoposide using a high-throughput, short-term cytotoxicity assay. The IC(50) was compared for population- and gender-specific differences for the four drugs. We observed large interindividual variance in IC(50) values for carboplatin, cisplatin, daunorubicin, and etoposide for both Yoruban and CEPH populations (range from 8- to 433-fold). Statistically significant differences in carboplatin and daunorubicin IC(50) were shown when comparing Yoruban cell lines (n = 89) to CEPH cell lines (n = 87; P = 0.002 and P = 0.029, respectively). This population difference in treatment induced cytotoxicity was not seen for either cisplatin or etoposide. In the Yoruban population, cell lines derived from females were less sensitive to platinating agents than males [median carboplatin IC(50), 29.1 versus 24.6 micromol/L (P = 0.012); median cisplatin IC(50), 7.0 versus 6.0 micromol/L (P = 0.020) in female and male, respectively]. This difference was not observed in the CEPH population. These results show that population and gender may affect risk for toxicities associated with certain chemotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.